News

LYMA Achieves Remarkable Growth in US Market with $48M Revenue

LYMA Achieves Remarkable Growth in US Market with $48M Revenue

LYMA Reports Achievements in 2025 with Impressive Revenue

LYMA, the luxury regenerative MedTech company, has announced remarkable financial results for the year ending December 31, 2025. The company saw strong revenue of $48 million, accompanied by an EBITDA of $7 million. This substantial growth has been fueled by the successful expansion into the United States market.

Strategic Expansion into the U.S. Market

The impressive performance underscores LYMA's strategic focus on the U.S. market, where the brand achieved significant momentum following the successful April 2025 launch of its LYMA PRO. The U.S. has emerged as a crucial growth area, representing over 70 percent of the brand's global sales due to increasing consumer demand for science-backed regenerative skincare technology.

Milestones Following the LYMA PRO Launch

After 18 months of investment focused on gaining FDA clearance, the LYMA PRO was successfully launched in the U.S. on April 15, 2025. This launch marked a significant turning point for LYMA, bringing with it a series of key milestones:

  1. Record-breaking waitlist: Thousands of interested customers joined LYMA's waitlist, with over 16,000 individuals representing demand exceeding $100 million for a device priced at nearly $6,000.
  2. Sales successes: Initial sales in the U.S. exceeded projections during the first week post-launch. The LYMA Laser PRO build on the success of its European launch, where it sold out twice. Direct-to-consumer (DTC) sales rose by 130% in the first six months following the launch.
  3. Retail partnerships: Major partnerships were established with reputable retailers like Revolve, FWRD, Goop, and Dermstore, enhancing the brand's reach across the U.S.
  4. Celebrity endorsements: U.S. icon Martha Stewart endorsed the LYMA Laser after experiencing the exclusive LYMA Lift treatment. Additionally, celebrity Sabrina Carpenter shared a photo on Instagram featuring her LYMA Laser PRO.
  5. Industry recognition: The LYMA Laser PRO received accolades across various beauty, science, and tech platforms, including recognition from prestigious publications.

Future Growth Plans

"2025 was a transformative year for LYMA as we solidified our position in the U.S. market and demonstrated the global appetite for truly innovative regenerative technology," shared Lucy Goff, Founder and CEO of LYMA. "This success reflects our commitment to delivering clinically-proven results through cutting-edge science, a demand that resonates strongly with American consumers."

LYMA's growth strategy is dedicated to building credibility through its scientific foundation while maintaining its premium positioning in the luxury wellness sector. Looking ahead, LYMA's performance in 2025 sets the stage for continued expansion throughout 2026, with plans to strengthen its presence in the U.S. and UK while exploring opportunities in key territories such as Australia and the UAE.

Commitment to Innovation

Lucy Goff, the founder, expressed gratitude to the LYMA team for their tireless efforts in ensuring that all products are innovative and scientifically backed. The enthusiasm for continued expansion in the U.S. and the introduction of new products later in 2026 is palpable.

The LYMA Laser PRO, favored by prominent figures including supermodels and award-winning actresses, has paved the way for brand innovation and credibility within both professional settings and among high-profile consumers. Its rapid acceptance is redefining the future landscape of skin health and rejuvenation.

Understanding the LYMA Laser PRO Technology

The LYMA Laser PRO technology boasts several cutting-edge features that underline its effectiveness:

  • Powered by a 1450mW near-infrared continuous cold laser beam at a wavelength of 808nm.
  • Penetrates deeply into the dermis, achieving significant lifting of both skin and muscle.
  • Delivers a proven dose of near-infrared laser light, ensuring effective treatments.
  • Designed for zero pain, zero damage, and no downtime.
  • Supported by 38 global patents and 5 published peer-reviewed studies.

Frequently Asked Questions

What drove LYMA's growth in 2025?

LYMA's growth in 2025 was primarily driven by its successful expansion into the U.S. market, particularly following the launch of the LYMA PRO laser.

Who is the founder of LYMA?

Lucy Goff is the founder and CEO of LYMA, and she has been instrumental in the company's innovative approach to regenerative skincare.

What technology powers the LYMA Laser PRO?

The LYMA Laser PRO utilizes a near-infrared continuous cold laser beam at a wavelength of 808nm, designed for deep penetration and effective results.

How has LYMA received recognition in the industry?

LYMA has received numerous awards and accolades from various beauty and technology platforms, underscoring its innovative products and dedication to quality.

What are LYMA's plans for the future?

LYMA plans to continue its expansion in the U.S. and UK while exploring opportunities in Australia and the UAE, alongside new product releases planned for 2026.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 37

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 40

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 52

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 28

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 46

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 63

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 35

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading

Top 5 Most Recently Viewed Articles

NORBIT Secures Significant NOK 120M Defence Order

Updated Category News Views 288

NORBIT Secures Significant NOK 120 Million Defence Order NORBIT has recently made an exciting announcement regarding a significant contract within its segment PIR. The company has been awarded a manufacturing order valued at NOK 120 million from a European client specializing in defence and security. This order is poised for delivery in late 2025 and early 2026, marking a...

Continue Reading
Shareholder Concerns Over BCO, SEM, NATL Transactions

Updated Category News Views 12

Is There Smoke Without Fire in Recent Company Mergers? Well, here we go again. It seems every time deals like these pop up, questions start flying about fairness and insider scoops. The big fish here? The Brink's Company (NYSE:BCO), Select Medical Holdings Corporation (NYSE:SEM), and NCR Atleos Corporation (NYSE:NATL). Halper Sadeh LLC, the investor rights firm, is on a...

Continue Reading
TG Therapeutics Director’s Recent Stock Sale Raises Questions

Updated Category News Views 120

Significant Insider Transaction at TG Therapeutics Recently, an important transaction came to light involving Yann Echelard, Director at TG Therapeutics (NASDAQ:TGTX). The details were revealed through the latest SEC filing. On a given date, Echelard sold 5,000 shares, raising a total of $162,850. Such insider trading can often prompt discussions regarding the company’s...

Continue Reading
Innovative Leadership in Facilities Management Revolutionized

Updated Category News Views 214

MasonMade Ventures Launches to Revamp Facilities Management Serial Entrepreneurs Aim to Disrupt the FM Industry through Innovative Software Solutions and Expert Trades MasonMade Ventures, established by visionary entrepreneurs Joseph Scaretta and Moses Carrasco, is set to change the face of facilities management. This operational holding company focuses on investing in...

Continue Reading
Kyverna Therapeutics Engages Investors at Upcoming Events

Updated Category News Views 136

Kyverna Therapeutics' Upcoming Investor Conferences Kyverna Therapeutics, Inc. (NASDAQ: KYTX), a pioneering clinical-stage biopharmaceutical company committed to innovative cell therapies for autoimmune diseases, is slated to present at a series of significant investor conferences this September. Warner Biddle, the Chief Executive Officer of Kyverna, will be the...

Continue Reading